Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Received Truth Turned On End In Cancer Research


It has long been the accepted view of cancer researchers that there is a difference between the mechanism behind the development of leukemias, on the one hand, and solid tumors like breast cancer, prostate cancer, gastrointestinal cancer, etc, on the other. A research team at the Section for Clinical Genetics at Lund University in Sweden is now claiming just the opposite: the same mechanism gives rise to all non-hereditary forms of cancer. These findings are being published in Nature Genetics.

A well-known mechanism for the development of cancer is that the chromosomes in a cell break apart and then recombine in an incorrect way. At the points of fissure, gene fragments are exposed that can recombine with so-called fusion genes, yielding fusion proteins. Leukemias--blood cancer--normally develop from cells that contain such fusion proteins. It is not known how this occurs in detail, but in some way the fusion proteins prompt formerly normal cells to transform into cancer cells. On the other hand, solid tumors, which make up the majority of all cancer cases, have been seen as developing as a result of certain cells losing the inhibiting mechanism in the form of so-called tumor suppressor genes that keep tumors from arising.

“This is no doubt correct in regard to hereditary cancer. But hereditary cancer accounts for only 5-10 percent of all cancer cases. We now maintain that all of the others have the same developmental mechanisms. In non-hereditary cancer forms it is the occurrence of fusion genes and not the lack of tumor suppressor genes that is essential,” says Professor Felix Mitelman.

Mitelman and his associates Bertil Johansson and Fredrik Mertens have gathered information about aberrant chromosomes in cancer for years. In 1997 Nature Genetics devoted an entire issue to the large material the Lund team had compiled, something that has only happened on one other occasion (when the human genome was presented). This material is now available as a large and constantly growing database in the so-called Cancer Genome Anatomy Project at the US National Cancer Institute, called the Mitelman Database of Chromosome Aberrations in Cancer.

In leukemia cells it is rather easy to find fusion genes and fusion proteins. For technical reasons, this is much more difficult in solid tumors.

“And if you haven’t seen them, you assume that they’re not there. But what has been lacking is appropriate methods of examination,” claims Felix Mitelman.

The research team has found that the number of fusion genes in solid tumors stands in the same proportion to the number of patient cases examined with leukemias. This shows that the same mechanisms are involved: the chance of this match being coincidental is less than 0.0001.

The good thing about this discovery is that it should lead to more effective treatment of the major cancer forms. For one type of leukemia, at any rate, there is a medicine that specifically targets the active fusion protein, and it is both effective and mild.

The downside is that there are probably a very great number of different fusion genes behind the major forms of cancer. Each transformation of genes is found in just a few patients.

“Small groups of patients are not of interest to pharmaceutical companies. On the other hand, it may be that several fusion proteins have common traits that make it possible to use the same drug to combat them,” hopes Felix Mitelman.

The fact that his research team have now turned on end an established truth does not mean that other ongoing research on the significance of genetic factors in the emergence of cancer has also been overturned, he emphasizes. Much of this research is about the long road from the first cancer cell to a full-blown tumor, and in this process tumor suppressor genes are probably of great importance. What the Lund team has done is to provide a revolutionary new picture of how this very first cancer cell arises.

Ingela Björck | alfa
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>